摘要
目的探讨伊马替尼联合化疗治疗ph+/bcr-abl+急性淋巴细胞性白血病(ALL)的疗效。方法ph+ALL患者12例,应用VDCP或VDCLP方案联合伊马替尼诱导治疗,完全缓解后伊马替尼与化疗交替进行巩固及强化治疗。结果12例ph+ALL完全缓解(CR)9例。总CR率75%。无治疗相关死亡。9例CR患者化疗与伊马替尼交替进行巩固及强化治疗,中位缓解期11(7～19)个月。结论伊马替尼联合化疗治疗Ph+ALL,CR率较常规化疗诱导治疗明显提高。化疗与伊马替尼交替进行巩固治疗,中位缓解时间及生存时间也较单用化疗明显延长。
Objective To study the efficacy of Imatinib in combination with chemotherepy in treatment of Ph ＋ ALL. Methods Patients with de novo ph ＋ ALL were adminstered to induction thera- py with VDCP or VDCLP in combination with imatinib and subsequently consolidation and maintenance therapy were started with imatinib and chemotherapy by turns after complete remission. Results Of 12 patients,9 patients achieved a CR. An overall CR rate was 75% ,moreover there was no death in con- nection with therapy. Estimated median remission duration was 11 （7 - 19 ） months. Conclusion In patients with Ph ＋ ALL given imatinib in combinaion with chemotherapy, CR rate is a significantly higher than that of conventional chemotherapy. In consolidation therapy with Imatinib and chemotherapy alternately, median remission and survival duration is improved compared with the chemotherapy.
出处
《医药论坛杂志》
2008年第24期49-50,共2页
Journal of Medical Forum
关键词
白血病
淋巴细胞
急性
bcr-abl+
伊马替尼
化疗
Acute
Lymphoblastic Leukemia
Chemotherapy
Bcr - abl ＋
Philadelphia Chromosome - Positive
